IGC Pharma expands AI-powered in-Silico drug discovery platform

IGC Pharma (IGC) announced an expansion of its AI-powered in-Silico drug discovery platform. The company is now integrating more methodologies, including retrosynthetic analysis, molecular docking, toxicology and genotoxic assessments, and predictive bioactivity modeling, to accelerate the identification and optimization of therapeutic candidates for Alzheimer’s disease and related disorders. This strategic enhancement aims to optimize the drug development process, reducing the time and resources traditionally required for compound screening and lead optimization. By leveraging AI-driven tools, IGC Pharma seeks to identify promising molecular structures within its patent portfolio more efficiently, predict their interactions with biological targets, and assess their potential efficacy and safety profiles early in the development cycle. IGC Pharma’s expanded platform includes: Toxicology and genotoxic assessments: Predict potential adverse effects of compounds, enabling early identification of toxicity risks and reducing reliance on animal testing. Predictive Bioactivity Modeling: Forecast the biological activity of compounds across various targets, including CB1, CB2, dopamine, serotonin, muscarinic, GLP-1, and GIP receptors. Molecular Docking Simulations: Predict the binding affinity and orientation of small molecules within target protein sites, aiding in the assessment of therapeutic potential. Retrosynthetic Analysis: Decomposing complex molecules into simpler precursors facilitates the design of feasible synthetic pathways.